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recommendations, yet tuned to the national context and the 
economic specificities of the country. 
The first work-packages of the HERO project have 
objectivized a large variation within European countries in 
resource availability and in actual needs for radiotherapy 
provision, related to the national cancer incidence. It also 
showed a remarkable lack of guidance for radiotherapy 
planning, with national recommendations mostly duplicating 
the available recommendations from international 
organizations or projects, without any attempt to streamline 
them to the needs of the individual country. 
Due to the growing awareness of resource limitations and 
tightening budgets, the weighing of costs and outcomes as 
performed in economic evaluations have become an integral 
part of the health resource allocation processes in many 
countries. Whereas cost-effectiveness data are typically 
required prior to the introduction of new drugs, they 
gradually also become more frequently requested to support 
radiotherapy financing. In order to make valid 
recommendations, the economic evaluations should however 
mimic the actual clinical and economic situation of the 
specific country. Yet, cost-effectiveness data from one 
country are not necessarily representative for another. 
The next step within the HERO-project is to develop a costing 
model that provides accurate radiotherapy resource cost 
data, based on the available resources, the cancer 
epidemiology and the radiotherapy practice of individual 
European countries. Time-driven activity-based costing, a 
cost-accounting method specifically developed to capture 
product complexity and variability, is highly suitable for that 
purpose. A final step will be to evaluate how these cost data 
can be combined with effectiveness data – derived from 
international studies but applicable to a country-specific 
environment – in an adaptable economic evaluation model, 
relevant for individual countries in the heterogeneous 
European context. 
   
SP-0395   
The equity gap in access to radiotherapy in the world. How 
do we close the divide? 
M. Gospodarowicz1 
1Princess Margaret Cancer Centre, Radiotherapy, Toronto, 
Canada 
 
Abstract not received. 
   
 
Proffered Papers: Radiobiology 3: Genetic predictors of 
tumour response  
 
 
OC-0396   
Identification of a microRNA signature associated with risk 
of distant metastasis in nasopharyngeal carcinoma 
F. Liu1, J. Bruce2, A. Hui3, W. Shi3, B. Perez-Ordonez4, W. 
Xu5, P. Boutros6, B. O'Sullivan1, J. Waldron1, S. Huang1 
1Princess Margaret Cancer Centre, Radiation Oncology, 
Toronto, Canada 
2University of Toronto, Medical Biophysics, Toronto, Canada  
3Princess Margaret Cancer Centre, Ontario Cancer Institute, 
Toronto, Canada  
4Princess Margaret Cancer Centre, Pathology, Toronto, 
Canada  
5Princess Margaret Cancer Centre, Biostatistics, Toronto, 
Canada  
6Ontario Institute for Cancer Research, Informatics and 
Biocomputing, Toronto, Canada  
 
Purpose/Objective: Despite significant improvement in 
locoregional control in the contemporary era of 
nasopharyngeal carcinoma (NPC) management, patients still 
suffer from a significant risk of distant metastasis (DM). 
Identifying those patients at risk of DM would aid in 
personalized treatment in the future. MicroRNAs (miRNAs) 
play many important roles in human cancers; hence, we 
proceeded to address the primary hypothesis that there is a 
miRNA expression signature capable of predicting DM for NPC 
patients. 
Materials and Methods: The expression of 734 miRNAs was 
measured in 125 (Training Set) and 121 (Validation Set) 
clinically annotated NPC diagnostic biopsy samples. 
Results: A 4-miRNA expression signature associated with risk 
of DM was generated by fitting a penalized Cox Proportion 
Hazard regression model to the Training data set (HR 8.25; 
p<0.001). This signature was subsequently tested in the 
Validation set, and maintained a significant relationship with 
DM (HR 3.2; p=0.01). In addition, multivariate analysis 
determined that this 4-miRNA signature was the strongest 
independent predictor when clinical factors were included. 
Finally, pathway enrichment analysis indicated that targets 
of the miRNAs comprising the final signature appear to be 
converging on cell cycle regulation. 
Conclusions: This 4-miRNA signature adds to the prognostic 
value of the current 'gold standard' of TNM staging. In-depth 
interrogation of these 4-miRNAs will provide important 
biological insights that could facilitate the discovery and 
development of novel molecularly targeted therapies to 
improve outcome for future NPC patients. 
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Purpose/Objective: Lysosome-associated membrane protein 
(LAMP)-3 is regulated by the unfolded protein response 
pathway. Our preclinical data suggest that LAMP3 plays an 
important role in autophagy induction during the response of 
breast cancer cells to various treatments and stress factors. 
We have shown that radiation therapy (RT), tamoxifen and 
hypoxia can induce LAMP3 and that high expression of LAMP3 
is associated with resistance to RT and tamoxifen in breast 
cancer cells. Moreover, patients with high levels of LAMP3 
mRNA had more locoregional recurrences. Here, we 
investigate the occurrence and clinical associations of a 
frequent non-synonymous single nucleotide polymorphism 
(SNP) in the LAMP3 gene (rs482912, Ile318Val) in 626 breast 
cancer patients. 
Materials and Methods: A custom TaqManÒ SNP Genotyping 
Assay targeted to our SNP of interest (rs482912) was used to 
assess its occurrence in breast cancer patients. We analysed 
the SNP's association with several clinical factors by Pearson 
Chi-square tests, and performed Kaplan-Meier survival and 
Cox regression analyses to investigate a relation with 
locoregional control. 
Results: In our cohort, the minor allele frequency for the 
LAMP3 rs482912SNP was 0.718, which is similar to the 
frequency in the European population. The SNP was not 
associated with menopausal status, type of operation, use of 
